Expert Analysis

Update on Hepatitis B Management

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Update on Hepatitis B Management

Faculty:

Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Patrick Marcellin, MD
Norah Terrault, MD, MPH

CME CREDIT INFORMATION

Release Date: 07/03/08

Expiration Date: 07/02/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the efficacy and safety of first-line therapies for the treatment of patients with chronic hepatitis B virus infection
Recount strategies for predicting response and management of suboptimal response to hepatitis B virus therapy
Describe data concerning the prevalence of nucleos(t)ide resistance in hepatitis B virus patients and strategies to manage it

Topics covered include:

Peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B
Predicting Responses to Peginterferon alfa-2a
Tenofovir vs Adefovir in Chronic Hepatitis B
Long-term Efficacy of Entecavir
Durability of HBeAg Seroconversion With Telbivudine or Lamivudine
Tenofovir-Based Regimens in Nucleos(t)ide-Experienced and Nucleos(t)ide-Refractory Patients
Adefovir Plus Lamivudine in Lamivudine-Resistant HBV
Long-term Entecavir in Chinese Patients With Lamivudine-Refractory HBV
Preexisting Resistance Mutations in Treatment-Naive Patients

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.